Norman Wolmark receives American Surgical Association Medallion for Advancement of Surgical Care

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Positive topline results have come out of the randomized phase II FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer who had received prior cyclin-dependent kinase 4/6 inhibitor-based treatment.

March 20, 2026

Vol.52 No.11

Clinical Roundup

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

The phase III persevERA Breast Cancer study, evaluating investigational giredestrant in combination with palbociclib for people with oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer, did not meet its primary objective of a statistically significant improvement in progression-free survival in the intent-to-treat population versus letrozole plus palbociclib, but a numerical improvement was observed.

March 13, 2026

Vol.52 No.10

Cancer Policy

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

Mount Sinai hospital has formed a committee to investigate the ties between Jeffrey Epstein and Eva Dubin a Swedish physician and philanthropist who founded the Dubin Breast Center at the Tisch Cancer Institute whose name is featured prominently in the Epstein files.

March 06, 2026

Vol.52 No.09

By Claire Marie Porter and Sara Willa Ernst

Clinical Roundup

TNBC can become resistant to therapy in more than one way, Baylor study finds

About 50% of triple-negative breast cancer patients develop resistance to therapy. When resistance arises, tumors are more likely to come back after the original treatment, significantly reducing the chances of survival.

March 06, 2026

Vol.52 No.09

Clinical Roundup

Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds

For many women with breast cancer, the treatment that saves their lives also brings fatigue that clings like a heavy coat, loss of muscle mass that turns everyday tasks into obstacles and emotional strain that lingers long after each infusion ends. It’s a season defined not just by survival, but by how well patients are able to live through it.

February 27, 2026

Vol.52 No.08

Norman Wolmark receives American Surgical Association Medallion for Advancement of Surgical Care

YOU MAY BE INTERESTED IN

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Atirmociclib combination produces positive topline results in phase II trial in second-line MBC indication

Phase III persevERA study of giredestrant combination in ER-positive advanced breast cancer does not meet primary objective

Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members

TNBC can become resistant to therapy in more than one way, Baylor study finds

Exercise during chemotherapy for breast cancer improves quality of life, Sylvester-led study finds

Renew today!

Subscriber content

Never miss an issue!

Login